The Tool Is Not the Quality System
The Tool Is Not the Quality System
There is a new kind of pressure showing up in pharma quality work.
Use AI.
Use automation.
Use smarter tools.
Move faster.
Fine.
Nobody serious is arguing that quality teams should keep doing everything the slowest possible way just because the old way feels familiar.
A recent preprint on GMPilot describes an AI agent built to help with FDA cGMP compliance work. The idea is straightforward enough: give quality professionals faster access to regulations, inspection observations, and structured compliance support.
That is useful.
It is also not the same thing as having a working quality system.
And that distinction matters.
Faster Access Is Not the Same as Better Judgment
A tool can help someone find an answer faster.
It can summarize.
It can retrieve.
It can organize.
It can point people toward relevant regulations, prior observations, or common inspection themes.
That is all valuable when the team knows what question it is trying to answer.
But quality work is rarely just a search problem.
The harder questions sound more like this:
• What is the actual risk?
• Who owns the decision?
• What evidence do we have?
• What evidence are we missing?
• Is this a one-off issue or a system signal?
• What happens if this same pattern shows up again?
• Would this explanation hold up in front of an inspector?
AI can support that work.
It cannot own it.
That part is still on the organization.
If the System Is Messy, the Tool Finds Mess Faster
This is where teams need to be careful.
A new tool can feel like progress because it creates activity.
More dashboards.
More summaries.
More outputs.
More things to paste into meetings.
That can look productive.
It can also become very expensive theater.
If deviations are poorly written, AI does not magically create root cause discipline.
If CAPAs are vague, AI does not magically create accountability.
If supplier files are incomplete, AI does not magically create supplier oversight.
If quality risk management is mostly a checkbox, AI does not magically create risk-based decision-making.
It may help people see the gap.
It may help people document the gap.
It may even help people explain the gap.
But the gap is still there.
The tool did not fix the system.
Q9 and Q10 Still Matter
This is why the boring foundations are still the foundations.
FDA's Q9(R1) guidance points teams back to quality risk management: decision-making, formality, subjectivity, product availability risk, and practical use of risk tools.
FDA's Q10 guidance describes the pharmaceutical quality system model: management responsibility, process performance, product quality monitoring, CAPA, change management, and continual improvement.
That is not old paperwork.
That is the operating model.
If an AI tool helps a team apply those principles more consistently, good.
Use it.
But if the tool becomes a substitute for those principles, the team has a problem.
Because inspectors do not just ask whether you had access to information.
They ask what you did with it.
They ask why.
They ask who decided.
They ask what changed.
They ask whether the correction actually worked.
A better search box will not carry that conversation by itself.
The Leadership Problem Does Not Go Away
The temptation with new technology is to treat it like a shortcut around hard management work.
It is not.
Quality leaders still have to make the system legible.
They still have to define ownership.
They still have to set standards for deviation quality, CAPA effectiveness, supplier oversight, validation evidence, and escalation.
They still have to decide what good looks like.
They still have to stop accepting vague answers because everyone is busy.
The tool can help the team move.
Leadership has to decide where they are moving and what standard they are moving toward.
That is the part people keep trying to outsource.
It usually does not go well.
A Practical Way to Think About AI in GMP
Before dropping AI into a quality process, ask a few plain questions:
• What decision is this tool supporting?
• What source material is it allowed to use?
• Who verifies the output?
• What happens when the output is wrong or incomplete?
• How will the team document use of the tool?
• What process owner is accountable for the result?
• Does this make the process clearer, or just faster?
That last one is the real test.
Speed without clarity is not improvement.
It is acceleration.
Sometimes that helps.
Sometimes it just gets the team to the wall faster.
Use the Tool. Own the System.
AI is going to have a place in pharma quality work.
It already does.
Teams should be curious about it.
They should test it.
They should learn where it helps and where it creates risk.
But they should not confuse a tool with a quality system.
The system is still the way people make decisions, manage risk, handle evidence, escalate problems, and prove that the work holds up.
AI can help with that.
It cannot replace that.
And if your quality system only works when a tool is doing the thinking for everyone, the issue is not the tool.
It is the system.
Start there.